Log In
Print
BCIQ
Print
Print this Print this
 

DNX-2401

  Manage Alerts
Collapse Summary General Information
Company DNAtrix Inc.
DescriptionGenetically modified oncolytic adenovirus that uses arginine-glycine-aspartic acid (RGD)-binding integrins to enter and replicate in tumor cells
Molecular Target
Mechanism of ActionOncolytic virus
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationBrain cancer
Indication DetailsTreat recurrent glioblastoma; Treat recurrent malignant glioma
Regulatory Designation

U.S. - Fast Track (Treat recurrent glioblastoma)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today